Overview

Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.
Phase:
N/A
Details
Lead Sponsor:
Hebei Yanda Hospital
Collaborator:
Beijing Tiantan Hospital
Treatments:
Bevacizumab
Dacarbazine
Temozolomide